Icares Medicus Inc (6612) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Icares Medicus Inc (6612) has a cash flow conversion efficiency ratio of -0.003x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-5.69 Million ≈ $-179.36K USD) by net assets (NT$2.00 Billion ≈ $62.99 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Icares Medicus Inc market capitalisation for the company's overall valuation and market capitalisation.
Icares Medicus Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Icares Medicus Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Icares Medicus Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Icares Medicus Inc ranked by their cash flow conversion efficiency. Explore how high is Icares Medicus Inc's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GBM Resources Ltd
AU:GBZ
|
-0.012x |
|
Dhampur Sugar Mills Limited
NSE:DHAMPURSUG
|
0.483x |
|
OncoQuest Pharmaceuticals Inc
KQ:078590
|
-0.019x |
|
Galantas Gold Corp
V:GAL
|
0.074x |
|
Brisbane Broncos Ltd
AU:BBL
|
0.160x |
|
ZHEJIANG SHIBAO H YC 1
F:W4K1
|
N/A |
|
Softstar Entertainment
TWO:6111
|
-0.024x |
|
Ifishdeco PT
JK:IFSH
|
0.057x |
Annual Cash Flow Conversion Efficiency for Icares Medicus Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Icares Medicus Inc from 2017 to 2025. View latest Icares Medicus Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$1.97 Billion ≈ $62.01 Million |
NT$-58.83 Million ≈ $-1.85 Million |
-0.030x | -8.59% |
| 2024-12-31 | NT$1.76 Billion ≈ $55.54 Million |
NT$-48.52 Million ≈ $-1.53 Million |
-0.028x | -78.13% |
| 2023-12-31 | NT$1.67 Billion ≈ $52.58 Million |
NT$-25.79 Million ≈ $-812.43K |
-0.015x | -111.24% |
| 2022-12-31 | NT$937.76 Million ≈ $29.54 Million |
NT$128.92 Million ≈ $4.06 Million |
0.137x | +192.61% |
| 2021-12-31 | NT$820.90 Million ≈ $25.86 Million |
NT$38.57 Million ≈ $1.22 Million |
0.047x | -53.76% |
| 2020-12-31 | NT$702.42 Million ≈ $22.13 Million |
NT$71.37 Million ≈ $2.25 Million |
0.102x | -25.26% |
| 2019-12-31 | NT$653.04 Million ≈ $20.57 Million |
NT$88.78 Million ≈ $2.80 Million |
0.136x | +22.87% |
| 2018-12-31 | NT$571.42 Million ≈ $18.00 Million |
NT$63.22 Million ≈ $1.99 Million |
0.111x | -18.11% |
| 2017-12-31 | NT$336.57 Million ≈ $10.60 Million |
NT$45.47 Million ≈ $1.43 Million |
0.135x | -- |
About Icares Medicus Inc
ICARES Medicus, Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of ophthalmic medical devices in Taiwan, the United States, United Kingdom, Japan, Spain, China, Germany, and internationally. The company is also involved in the manufacturing, sales, and service of intraocular lenses (IOLs) and its implantation systems for use in treating cataract… Read more